Healthcare AI regulation must follow the product as it changes
A piece in Innovation News Network argues that healthcare AI regulation needs to be dynamic, tracking products as they evolve rather than locking in rules at the point of initial approval. The core concern is that AI systems in clinical settings can change significantly after deployment.
Why this matters: Medical AI is not like a drug that stays the same after approval. These systems can be retrained, updated, and quietly changed after they are already being used on patients. Regulators currently approve a version of a product, not the product as it will exist in six months. That gap is real. If a diagnostic tool shifts its behavior after an update and a patient is harmed, it needs to be clear who is responsible and whether anyone was watching.
Who should care: AI governance · Lawyers · Administrators · Compliance · General readers · Policy
This summary is AI-assisted and may contain errors. It is an original briefing to help you gauge significance quickly — not a reproduction of the source. Always read the linked original before relying on it. See our methodology.